Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer

J Enzyme Inhib Med Chem. 2010 Apr;25(2):158-71. doi: 10.3109/14756360903169485.

Abstract

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor-2 (VEGFR-2), two protein tyrosine kinases, are involved in pathological disorders and the progression of different types of carcinomas. Concomitant inhibition of both tyrosine kinase activities appears to be an attractive target for cancer chemotherapy. A series of new quinazoline derivatives substituted by amide, urea, or carbamic acid ester groups have been synthesized. The biological activities of these new compounds have been evaluated for their enzyme inhibition and antiproliferative activities.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / chemistry
  • Antineoplastic Agents* / chemical synthesis
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Carbamates / chemistry
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Drug Screening Assays, Antitumor
  • ErbB Receptors / antagonists & inhibitors*
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / enzymology
  • Protein Kinase Inhibitors* / chemical synthesis
  • Protein Kinase Inhibitors* / chemistry
  • Protein Kinase Inhibitors* / pharmacology
  • Quinazolines* / chemical synthesis
  • Quinazolines* / chemistry
  • Quinazolines* / pharmacology
  • Urea / chemistry*
  • Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors*

Substances

  • Amides
  • Antineoplastic Agents
  • Carbamates
  • Protein Kinase Inhibitors
  • Quinazolines
  • Urea
  • ErbB Receptors
  • Vascular Endothelial Growth Factor Receptor-2
  • carbamic acid